Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy

키워드

참고문헌 (119)

1. Josefowicz SZ, "Regulatory T cells : mechanisms of differentiation and function", Annu Rev Immunol, 30, pp.531~564 (2012)
2. Fontenot JD, "Foxp3 programs the development and function of CD4+CD25+ regulatory T cells", Nat Immunol, 4, pp.330~336 (2003)
3. Hori S, "Control of regulatory T cell development by the transcription factor Foxp3", Science, 299, pp.1057~1061 (2003)
4. Bennett CL, "The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome(IPEX)is caused by mutations of FOXP3", Nat Genet, 27, pp.20~21 (2001)
5. Motz GT, "Deciphering and reversing tumor immune suppression", Immunity, 39, pp.61~73 (2013)
6. Baecher-Allan C, "CD4+CD25high regulatory cells in human peripheral blood", J Immunol, 167, pp.1245~1253 (2001)
7. Spranger S, "Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells", Sci Transl Med, 5, pp.200~ (2013)
8. Williams JB, "The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment", J Exp Med, 214, pp.381~400 (2017)
9. Pardoll DM, "The blockade of immune checkpoints in cancer immunotherapy", Nat Rev Cancer, 12, pp.252~264 (2012)
10. Zou W, "PD-L1(B7-H1)and PD-1 pathway blockade for cancer therapy : mechanisms, response biomarkers, and combinations", Sci Transl Med, 8, pp.328~ (2016)
11. Brahmer JR, "Safety and activity of anti-PD-L1 antibody in patients with advanced cancer", N Engl J Med, 366, pp.2455~2465 (2012)
12. Hodi FS, "Improved survival with ipilimumab in patients with metastatic melanoma", N Engl J Med, 363, pp.711~723 (2010)
13. Topalian SL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer", N Engl J Med, 366, pp.2443~2454 (2012)
14. Togashi Y, "Regulatory T cells : molecular and cellular basis for immunoregulation", Curr Top Microbiol Immunol, 410, pp.3~27 (2017)
15. Sakaguchi S, "FOXP3+ regulatory T cells in the human immune system", Nat Rev Immunol, 10, pp.490~500 (2010)
16. Hsieh CS, "An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires", Nat Immunol, 7, pp.401~410 (2006)
17. Wong J, "Adaptation of TCR repertoires to self-peptides in regulatory and nonregulatory CD4+ T cells", J Immunol, 178, pp.7032~7041 (2007)
18. Yadav M, "Peripherally induced Tregs-role in immune homeostasis and autoimmunity", Front Immunol, 4, pp.232~ (2013)
19. Ziegler SF, "FOXP3 : of mice and men", Annu Rev Immunol, 24, pp.209~226 (2006)
20. Roychoudhuri R, "BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis", Nature, 498, pp.506~510 (2013)
21. Igarashi K, "BACH transcription factors in innate and adaptive immunity", Nat Rev Immunol, 17, pp.437~450 (2017)
22. Kim EH, "Bach2 regulates homeostasis of Foxp3+ regulatory T cells and protects against fatal lung disease in mice", J Immunol, 192, pp.985~995 (2014)
23. Overacre-Delgoffe AE, "Interferon-γ drives Treg fragility to promote anti-tumor immunity", Cell, 169, pp.1130~1141 (2017)
24. Sarris M, "Neuropilin-1 expression on regulatory T cells enhances their interactions with dendritic cells during antigen recognition", Immunity, 28, pp.402~413 (2008)
25. Getnet D, "A role for the transcription factor Helios in human CD4+CD25+ regulatory T cells", Mol Immunol, 47, pp.1595~1600 (2010)
26. Zheng Y, "Role of conserved non-coding DNA elements in the Foxp3 gene in regulatory T-cell fate", Nature, 463, pp.808~812 (2010)
27. Lathrop SK, "Antigen-specific peripheral shaping of the natural regulatory T cell population", J Exp Med, 205, pp.3105~3117 (2008)
28. Tran DQ, "Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor-beta dependent but does not confer a regulatory phenotype", Blood, 110, pp.2983~2990 (2007)
29. Liu W, "CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells", J Exp Med, 203, pp.1701~1711 (2006)
30. Seddiki N, "Expression of interleukin(IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells", J Exp Med, 203, pp.1693~1700 (2006)
31. Miyara M, "Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor", Immunity, 30, pp.899~911 (2009)
32. Thornton AM, "CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production", J Exp Med, 188, pp.287~296 (1998)
33. Takahashi T, "Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells : induction of autoimmune disease by breaking their anergic", suppressive state, 1998, pp.10, 1969~1980
34. Steinbrink K, "Induction of tolerance by IL-10-treated dendritic cells", J Immunol, 159, pp.4772~4780 (1997)
35. Collison LW, "The inhibitory cytokine IL-35 contributes to regulatory T-cell function", Nature, 450, pp.566~569 (2007)
36. Turnis ME, "Interleukin-35 limits anti-tumor immunity", Immunity, 44, pp.316~329 (2016)
37. Jarnicki AG, "Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor : influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells", J Immunol, 177, pp.896~904 (2006)
38. Deaglio S, "Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression", J Exp Med, 204, pp.1257~1265 (2007)
39. Wilson JM, "The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells", J Immunol, 182, pp.4616~4623 (2009)
40. Uyttenhove C, "Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2, 3-dioxygenase", Nat Med, 9, pp.1269~1274 (2003)
41. Saleh R, "Treg-mediated acquired resistance to immune checkpoint inhibitors", Cancer Lett, 457, pp.168~179 (2019)
42. Burchell JT, "The role of dendritic cells and regulatory T cells in the regulation of allergic asthma", Pharmacol Ther, 125, pp.1~10 (2010)
43. Wing K, "CTLA-4 control over Foxp3+ regulatory T cell function", Science, 322, pp.271~275 (2008)
44. Schubert D, "Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations", Nat Med, 20, pp.1410~1416 (2014)
45. Kuehn HS, "Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4", Science, 345, pp.1623~1627 (2014)
46. Perez VL, "Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement", Immunity, 6, pp.411~417 (1997)
47. Onizuka S, "Tumor rejection by in vivo administration of anti-CD25(interleukin-2 receptor alpha)monoclonal antibody", Cancer Res, 59, pp.3128~3133 (1999)
48. Shimizu J, "Induction of tumor immunity by removing CD25+CD4+ T cells : a common basis between tumor immunity and autoimmunity", J Immunol, 163, pp.5211~5218 (1999)
49. Tada Y, "Targeting VEGFR2 with Ramucirumab strongly impacts effector", activated regulatory T cells and CD8+ T cells in the tumor microenvironment, 2018, pp.6, 106~
50. Saito T, "Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers", Nat Med, 22, pp.679~684 (2016)
51. Akimova T, "Human lung tumor FOXP3+ Tregs upregulate four"Treg-locking"transcription factors", JCI Insight, 2, pp.94075~ (2017)
52. Curiel TJ, "Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival", Nat Med, 10, pp.942~949 (2004)
53. Takeuchi Y, "Roles of regulatory T cells in cancer immunity", Int Immunol, 28, pp.401~409 (2016)
54. Gobert M, "Regulatory T cells recruited through CCL22", CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome, 2009, pp.69, 2000~2009
55. Tan MC, "Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer", J Immunol, 182, pp.1746~1755 (2009)
56. Kryczek I, "Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma", Cancer Res, 67, pp.8900~8905 (2007)
57. Ladoire S, "Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas : the paradox of colorectal cancer", Cancer Immunol Immunother, 60, pp.909~918 (2011)
58. Salama P, "Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer", J Clin Oncol, 27, pp.186~192 (2009)
59. Badoual C, "Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers", Clin Cancer Res, 12, pp.465~472 (2006)
60. Petersen RP, "Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients", Cancer, 107, pp.2866~2872 (2006)
61. Marshall EA, "Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis", Mol Cancer, 15, pp.67~ (2016)
62. Fridman WH, "The immune contexture in human tumours : impact on clinical outcome", Nat Rev Cancer, 12, pp.298~306 (2012)
63. Sugiyama D, "Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans", Proc Natl Acad Sci U S A, 110, pp.17945~17950 (2013)
64. De Simone M, "Transcriptional landscape of human tissue lymphocytes unveils uniqueness of tumor-infiltrating T regulatory cells", Immunity, 45, pp.1135~1147 (2016)
65. Nishikawa H, "Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells", J Exp Med, 201, pp.681~686 (2005)
66. Nishikawa H, "IFN-gamma controls the generation", activation of CD4+ CD25+ regulatory T cells in antitumor immune response, 2005, pp.175, 4433~4440
67. Pace L, "Regulatory T cells increase the avidity of primary CD8+ T cell responses and promote memory", Science, 338, pp.532~536 (2012)
68. Maeda Y, "Detection of self-reactive CD8+ T cells with an anergic phenotype in healthy individuals", Science, 346, pp.1536~1540 (2014)
69. Nishikawa H, "Regulatory T cells in cancer immunotherapy", Curr Opin Immunol, 27, pp.1~7 (2014)
70. Kurose K, "Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients", Clin Cancer Res, 21, pp.4327~4336 (2015)
71. Jia Z, "A novel splice variant of FR4 predominantly expressed in CD4+CD25+ regulatory T cells", Immunol Invest, 38, pp.718~729 (2009)
72. Miyara M, "Sialyl Lewis x(CD15s)identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humans", Proc Natl Acad Sci U S A, 112, pp.7225~7230 (2015)
73. Foss F, "Clinical experience with denileukin diftitox(ONTAK)", Semin Oncol, 33, pp.S11~ (2006)
74. Steitz J, "Depletion of CD25+ CD4+ T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8+ T-cell-dependent immune defense of B16 melanoma", Cancer Res, 61, pp.8643~8646 (2001)
75. Rech AJ, "CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients", Sci Transl Med, 4, pp.134~ (2012)
76. Jacobs JF, "Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment : a phase I", II study in metastatic melanoma patients, 2010, pp.16, 5067~5078
77. Romano E, "Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients", Proc Natl Acad Sci U S A, 112, pp.6140~6145 (2015)
78. Ribas A, "Tumor immunotherapy directed at PD-1", N Engl J Med, 366, pp.2517~2519 (2012)
79. Arce Vargas F, "Fc effector function contributes to the activity of human anti-CTLA-4 antibodies", Cancer Cell, 33, pp.649~663 (2018)
80. Bulliard Y, "Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies", J Exp Med, 210, pp.1685~1693 (2013)
81. Selby MJ, "Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells", Cancer Immunol Res, 1, pp.32~42 (2013)
82. Simpson TR, "Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma", J Exp Med, 210, pp.1695~1710 (2013)
83. van Olffen RW, "GITR triggering induces expansion of both effector and regulatory CD4+ T cells in vivo", J Immunol, 182, pp.7490~7500 (2009)
84. Nishikawa H, "Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling", Cancer Res, 68, pp.5948~5954 (2008)
85. Buchan SL, "The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy", Blood, 131, pp.39~48 (2018)
86. Curti BD, "OX40 is a potent immune-stimulating target in late-stage cancer patients", Cancer Res, 73, pp.7189~7198 (2013)
87. Herman AE, "CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion", J Exp Med, 199, pp.1479~1489 (2004)
88. Burmeister Y, "ICOS controls the pool size of effector-memory and regulatory T cells", J Immunol, 180, pp.774~782 (2008)
89. Nagase H, "ICOS+ Foxp3+ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with Helicobacter pylori", Int J Cancer, 140, pp.686~695 (2017)
90. Burris HA, "Phase 1 safety of ICOS agonist antibody JTX-2011 alone and with nivolumab(nivo)in advanced solid tumors; predicted vs observed pharmacokinetics(PK)in ICONIC", J Clin Oncol, 35, pp.3033~ (2017)
91. Kurtulus S, "TIGIT predominantly regulates the immune response via regulatory T cells", J Clin Invest, 125, pp.4053~4062 (2015)
92. Joller N, "Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses", Immunity, 40, pp.569~581 (2014)
93. Johnston RJ, "The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function", Cancer Cell, 26, pp.923~937 (2014)
94. Scurr M, "Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3-T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells", Mucosal Immunol, 7, pp.428~439 (2014)
95. Anderson AC, "Lag-3, Tim-3, and TIGIT : co-inhibitory receptors with specialized functions in immune regulation", Immunity, 44, pp.989~1004 (2016)
96. Zhu C, "The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity", Nat Immunol, 6, pp.1245~1252 (2005)
97. Das M, "Tim-3 and its role in regulating anti-tumor immunity", Immunol Rev, 276, pp.97~111 (2017)
98. Sakuishi K, "TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer", OncoImmunology, 2, pp.e23849~ (2013)
99. Campbell DJ, "Phenotypical and functional specialization of FOXP3+ regulatory T cells", Nat Rev Immunol, 11, pp.119~130 (2011)
100. Ishida T, "CCR4 as a novel molecular target for immunotherapy of cancer", Cancer Sci, 97, pp.1139~1146 (2006)
101. Nishikawa H, "Regulatory T cells in tumor immunity", Int J Cancer, 127, pp.759~767 (2010)
102. Kurose K, "Anti-CCR4 mAb and regulatory T cells", Gan To Kagaku Ryoho, 40, pp.1150~1155 (2013)
103. Zhang B, "Nonoverlapping roles of PD-1 and FoxP3 in maintaining immune tolerance in a novel autoimmune pancreatitis mouse model", Proc Natl Acad Sci U S A, 113, pp.8490~8495 (2016)
104. Gianchecchi E, "Inhibitory receptors and pathways of lymphocytes : the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression", Front Immunol, 9, pp.2374~ (2018)
105. Kamada T, "PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer", Proc Natl Acad Sci U S A, 116, pp.9999~10008 (2019)
106. Colak S, "Targeting TGF-β signaling in cancer", Trends Cancer, 3, pp.56~71 (2017)
107. Holmgaard RB, "Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade", J Immunother Cancer, 6, pp.47~ (2018)
108. Strauss J, "Phase I trial of M7824(MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors", Clin Cancer Res, 24, pp.1287~1295 (2018)
109. Ahmad S, "Differential PI3Kδ signaling in CD4+ T-cell subsets enables selective targeting of T regulatory cells to enhance cancer immunotherapy", Cancer Res, 77, pp.1892~1904 (2017)
110. Ali K, "Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer", Nature, 510, pp.407~411 (2014)
111. Huynh A, "Control of PI(3)kinase in Treg cells maintains homeostasis and lineage stability", Nat Immunol, 16, pp.188~196 (2015)
112. Shrestha S, "Treg cells require the phosphatase PTEN to restrain TH1 and TFH cell responses", Nat Immunol, 16, pp.178~187 (2015)
113. Imagawa J, "Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year(DADI trial) : a multicentre phase 2 trial", Lancet Haematol, 2, pp.e528~ (2015)
114. Vahl JC, "Continuous T cell receptor signals maintain a functional regulatory T cell pool", Immunity, 41, pp.722~736 (2014)
115. Ohta A, "Extracellular adenosine-mediated modulation of regulatory T cells", Front Immunol, 5, pp.304~ (2014)
116. Terme M, "VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer", Cancer Res, 73, pp.539~549 (2013)
117. Zhu P, "The role and significance of VEGFR2+ regulatory T cells in tumor immunity", Onco Targets Ther, 10, pp.4315~4319 (2017)
118. Roland CL, "Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer", PLoS One, 4, pp.e7669~ (2009)
119. Voron T, "VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors", J Exp Med, 212, pp.139~148 (2015)

관련 논문AI추천